Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 19;78:100152. doi: 10.1016/j.clinsp.2022.100152

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 HCFMUSP. Published by Elsevier España, S.L.U.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig 8 — Comparison of gefitinib in combination with chemotherapy versus gefitinib alone in patients with EGFR mutations. The following outcomes of gefitinib in combination with chemotherapy and gefitinib alone were compared in patients with EGFR mutations: (A) Objective Response Rate (ORR); OR (Odds Ratio) > 1 indicates gefitinib in combination with chemotherapy has higher probability of ORR as compared with gefitinib alone; (B) Disease Control Rate (DCR); OR > 1 indicates gefitinib in combination with chemotherapy has higher probability of DCR as compared with gefitinib alone; (C) Progression-Free Survival (PFS); HR > 1 indicates gefitinib in combination with chemotherapy has higher probability of progression-free survival as compared with gefitinib alone; and (D) Overall Survival (OS); HR > 1 indicates gefitinib in combination with chemotherapy has higher probability of overall survival as compared with gefitinib alone.